Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange.
暂无分享,去创建一个
S. Carr | M. Minnich | J. Culp | T. Tomaszek | M. L. Moore | S A Carr | T A Tomaszek | M D Minnich | J S Culp | G D Roberts | S. Fakhoury | G. Roberts | Victoria W. Magaard | L. Hyland | L J Hyland | V W Magaard | H L Bryan | S A Fakhoury | M L Moore | V. Magaard | H. L. Bryan | Michael L. Moore | Jeffrey S. Culp | Gerald D. Roberts | Steven A. Carr
[1] W. Cleland. Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies. , 2006, Advances in enzymology and related areas of molecular biology.
[2] J S Fruton,et al. The mechanism of the catalytic action of pepsin and related acid proteinases. , 2006, Advances in enzymology and related areas of molecular biology.
[3] V K Antonov,et al. Studies on the mechanisms of action of proteolytic enzymes using heavy oxygen exchange. , 2005, European journal of biochemistry.
[4] R. Dixon,et al. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.
[5] M. Minnich,et al. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease. , 1991, Biochemistry.
[6] A Wlodawer,et al. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.
[7] A Wlodawer,et al. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Norbeck,et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.
[9] T. Meek,et al. A radiometric assay for HIV-1 protease. , 1990, Analytical biochemistry.
[10] M. Paberit. Kinetic salting effect as a promising tool in the investigation of enzyme molecule changes upon reaction: Deacylation of acyl-chymotrypsins , 1990 .
[11] W. Farmerie,et al. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. , 1990, The Journal of biological chemistry.
[12] G R Marshall,et al. Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.
[13] P. Kollman,et al. Atomic charges derived from semiempirical methods , 1990 .
[14] I B Duncan,et al. Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.
[15] T. Meek,et al. Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease. , 1990, Biochemical and biophysical research communications.
[16] Tomi K. Sawyer,et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.
[17] Brian W. Metcalf,et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues , 1990, Nature.
[18] C. Debouck,et al. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. Debouck,et al. Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. , 1989, Archives of biochemistry and biophysics.
[20] M. Jaskólski,et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.
[21] J. Sodroski,et al. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[22] B. Ho,et al. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.
[23] C. Debouck,et al. Peptide substrates and inhibitors of the HIV-1 protease. , 1989, Biochemical and biophysical research communications.
[24] C. Debouck,et al. Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[26] Maria Miller,et al. Crystal structure of a retroviral protease proves relationship to aspartic protease family , 1989, Nature.
[27] D. Veber,et al. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.
[28] T. Copeland,et al. Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne) , 1988, Journal of virology.
[29] S. Kent,et al. Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease , 1988, Cell.
[30] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[31] C. Debouck,et al. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[32] E. Padlan,et al. Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[33] William R. Taylor,et al. A structural model for the retroviral proteases , 1987, Nature.
[34] L. Polgár. The mechanism of action of aspartic proteases involves ‘push‐pull’ catalysis , 1987, FEBS letters.
[35] J. Coligan,et al. Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus , 1986, Journal of virology.
[36] S. Devare,et al. Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24 , 1985, Journal of virology.
[37] M. James,et al. Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. , 1985, Biochemistry.
[38] V. Kostka. Aspartic proteinases and their inhibitors : proceedings of the FEBS advanced course no. 84/07, Prague, Czechoslovakia, August 20-24, 1984 , 1985 .
[39] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[40] D. Davies,et al. Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5-A resolution. , 1982, Biochemistry.
[41] W. Cleland,et al. pH variation of isotope effects in enzyme-catalyzed reactions. 1. Isotope- and pH-dependent steps the same. , 1981, Biochemistry.
[42] S. Litwin,et al. Correction of scrambling rate calculation for loss of substrate. , 1979, The Journal of biological chemistry.
[43] V. Antonov,et al. Mechanism of pepsin catalysis: General base catalysis by the active‐site carboxylate ion , 1978, FEBS letters.
[44] T. T. Wang,et al. Acyl and amino intermediates in reactions catalysed by pig pepsin. Analysis of transpeptidation products. , 1976, Biochemical Journal.
[45] S. Cha,et al. Tight-binding inhibitors-I. Kinetic behavior. , 1975, Biochemical pharmacology.
[46] W. Cleland. Partition analysis and the concept of net rate constants as tools in enzyme kinetics. , 1975, Biochemistry.
[47] J. Knowles,et al. Acyl- and amino-transfer routes in pepsin-catalyzed reactions , 1975 .
[48] T. T. Wang,et al. Acyl intermediates in pepsin and penicillopepsin catalyzed reactions. , 1974, Biochemical and biophysical research communications.
[49] J. Knowles,et al. The inhibition of pepsin-catalysed reactions by structural and stereochemical product analogues. , 1971, Biochemical Journal.
[50] A. Berger,et al. Mapping the active site of papain with the aid of peptide substrates and inhibitors. , 1970, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[51] J. Fruton,et al. The inhibition of pepsin action. , 1968, Biochemistry.
[52] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[53] V. Potter,et al. Enzyme Inhibition in Relation to Chemotherapy.∗ , 1949, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[54] K. Biemann. Sequencing of peptides by tandem mass spectrometry and high-energy collision-induced dissociation. , 1990, Methods in enzymology.
[55] C. Debouck,et al. Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli , 1989, Proteins.
[56] I. A. Rose. Positional isotope exchange studies of enzyme mechanisms. , 1979, Advances in enzymology and related areas of molecular biology.
[57] P. Deslongchamps. Stereoelectronic control in the cleavage of tetrahedral intermediates in the hydrolysis of esters and amides , 1975 .
[58] W. Cleland. The kinetics of enzyme-catalyzed reactions with two or more substrates or products. I. Nomenclature and rate equations. , 1963, Biochimica et biophysica acta.